PharmaShots | Incisive News in 3 Shots

Subscribe Now

nmCRPC

Bayer Reports Results of Darolutamide in P-III ARAMIS trial for Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)

Bayer Reports Results of Darolutamide in P-III ARAMIS trial for Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)

February 15, 2019

Astellas' Xtandi (enzalutamide) Receives EU's Approval for Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)

Astellas' Xtandi (enzalutamide) Receives EU's Approval for Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer...

October 30, 2018

Orion's Darolutamide Achieves 1EP in P-III ARAMIS study in Men with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)

Orion's Darolutamide Achieves 1EP in P-III ARAMIS study in Men with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)

October 25, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us